A detailed history of Diametric Capital, LP transactions in Ocuphire Pharma, Inc. stock. As of the latest transaction made, Diametric Capital, LP holds 33,251 shares of OCUP stock, worth $32,585. This represents 0.02% of its overall portfolio holdings.

Number of Shares
33,251
Previous 38,035 12.58%
Holding current value
$32,585
Previous $58,000 25.86%
% of portfolio
0.02%
Previous 0.04%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$1.19 - $2.07 $5,692 - $9,902
-4,784 Reduced 12.58%
33,251 $43,000
Q2 2024

Aug 13, 2024

SELL
$1.51 - $2.23 $20,172 - $29,790
-13,359 Reduced 25.99%
38,035 $58,000
Q1 2024

May 15, 2024

SELL
$1.89 - $3.27 $41,460 - $71,733
-21,937 Reduced 29.92%
51,394 $103,000
Q4 2023

Feb 13, 2024

BUY
$2.59 - $3.64 $44,734 - $62,870
17,272 Added 30.81%
73,331 $220,000
Q3 2023

Nov 14, 2023

BUY
$3.35 - $4.33 $93,284 - $120,573
27,846 Added 98.7%
56,059 $187,000
Q2 2023

Aug 11, 2023

SELL
$3.63 - $6.38 $99,589 - $175,035
-27,435 Reduced 49.3%
28,213 $122,000
Q1 2023

May 11, 2023

BUY
$3.01 - $3.85 $96,470 - $123,392
32,050 Added 135.82%
55,648 $208,000
Q4 2022

Mar 29, 2023

SELL
$2.04 - $3.53 $1,938 - $3,353
-950 Reduced 3.87%
23,598 $83,000
Q3 2022

Nov 14, 2022

SELL
$1.82 - $2.79 $17,850 - $27,364
-9,808 Reduced 28.55%
24,548 $49,000
Q2 2022

Aug 15, 2022

SELL
$1.8 - $3.25 $30,915 - $55,818
-17,175 Reduced 33.33%
34,356 $66,000
Q1 2022

May 16, 2022

SELL
$2.75 - $4.39 $104,255 - $166,429
-37,911 Reduced 42.39%
51,531 $166,000
Q4 2021

Feb 14, 2022

BUY
$3.4 - $5.19 $304,102 - $464,203
89,442 New
89,442 $334,000

Others Institutions Holding OCUP

About Ocuphire Pharma, Inc.


  • Ticker OCUP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,579,800
  • Market Cap $20.2M
  • Description
  • Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical tr...
More about OCUP
Track This Portfolio

Track Diametric Capital, LP Portfolio

Follow Diametric Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Diametric Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Diametric Capital, LP with notifications on news.